The resulting goodwill may prove useful to Pfizer and Moderna.
Within 24 hours of emergency authorization from the Food and Drug Administration, the vaccine maker Pfizer plans to move the product to patients nationwide.
Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December.
The COVID-19 vaccine is being produced so quickly due to a combination of factors involving the research community, government, industry and the public.
At first, COVID-19 vaccines won't be marketed in the usual sense, because the government will be the main buyer.